Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases
Open Access
- 6 May 2015
- journal article
- research article
- Published by Springer Nature in Radiation Oncology
- Vol. 10 (1) , 1-7
Abstract
Lobular carcinomas in situ (LCIS) represent 1-2% of all breast cancers. Both significance and treatment remain widely debated, as well as the possible similarities with DCIS. Two hundred patients with pure LCIS were retrospectively analyzed in seven centres from 1990 to 2008. Median age was 52 years; 176 patients underwent breast-conserving surgery (BCS) and 24 mastectomy. Seventeen patients received whole breast irradiation (WBRT) after BCS and 20 hormonal treatment (15 by tamoxifen). With a 144-month median follow-up (FU), there were no local recurrences (LR) among 24 patients treated by mastectomy. With the same FU, 3 late LR out of 17 (17%) occurred in patients treated by BCS and WBRT (with no LR at 10 years). Among 159 patients treated by BCS alone, 20 developed LR (13%), but with only a 72-month FU (17.5% at 10 years). No specific LR risk factors were identified. Three patients developed metastases, two after invasive LR; 22 patients (11%) developed contralateral BC (59% invasive) and another five had second cancer. LCIS is not always an indolent disease. The long-term outcome is quite similar to most ductal carcinomas in situ (DCIS). The main problems are the accuracy of pathological definition and a clear identification of more aggressive subtypes, in order to avoid further invasive LR. BCS + WBRT should be discussed in some selected cases, and the long-term results seem comparable to DCIS.Keywords
This publication has 44 references indexed in Scilit:
- Radiotherapy in DCIS, an underestimated benefit?Radiotherapy and Oncology, 2014
- Lobular NeoplasiaSurgical Oncology Clinics of North America, 2014
- Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast–A reviewEuropean Journal of Surgical Oncology, 2011
- Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trialThe Lancet Oncology, 2011
- Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma In Situ DiagnosisJNCI: Journal of the National Cancer Institute, 2010
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 TrialJAMA, 2006
- Should patients with lobular carcinoma in situ be irradiated? – not yet, but....European Journal of Cancer, 2005
- Breast-conserving surgery and radiotherapy: a possible treatment for lobular carcinoma in situ?European Journal of Cancer, 2005
- The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor RegistryThe Breast, 2003
- Lobular Carcinoma In Situ of the Female BreastAmerican Journal of Surgical Pathology, 1993